| Topic | Current understanding | Key evidence (with citation IDs) | Key recent sources (year; DOI/URL if in evidence) |
|---|---|---|---|
| Protein size / processing | Human MGP (UniProt P08493) is an 84-aa, ~11–12 kDa secreted extracellular matrix Gla-family protein made as a precursor with a signal peptide; literature consistently places it in the osteocalcin/MGP family and describes extracellular function in vessel wall/cartilage matrices. | 84-aa secreted ECM protein; extracellular localization; family-consistent Gla protein features (pqac-00000000, pqac-00000002, pqac-00000003) | Galunska et al., 2024, *Int J Mol Sci*; https://doi.org/10.3390/ijms25063517. Lau, 2025 thesis/source (no DOI in evidence). |
| PTMs: γ-carboxylation | MGP activity depends on vitamin K–dependent γ-carboxylation of 5 Glu residues, commonly reported at positions 2, 37, 41, 47/48, and 52. Carboxylation is essential for Ca²⁺/mineral binding and anti-calcification activity; warfarin or loss of carboxylation causes inactive MGP and severe ectopic calcification in models. | Specific Gla positions and carboxylation dependence; loss-of-function/warfarin evidence (pqac-00000000, pqac-00000002, pqac-00000004, pqac-00000005) | Galunska et al., 2024; https://doi.org/10.3390/ijms25063517. Neofytou et al., 2024; https://doi.org/10.3390/nu16121798. |
| PTMs: phosphorylation | Three N-terminal serines (Ser3, Ser6, Ser9) are phosphorylated. Phosphorylation helps define circulating/functional isoforms and likely modulates local conformation, secretion/mineral interaction, and full activity; p-cMGP is considered the fully active form, whereas dp-ucMGP is fully inactive. | Ser3/6/9 phosphorylation and isoform logic (pqac-00000000, pqac-00000001, pqac-00000005, pqac-00000022) | Galunska et al., 2024; https://doi.org/10.3390/ijms25063517. Figure summarizing isoforms and effects (pqac-00000022). |
| Major mechanism: hydroxyapatite binding / inhibition | Carboxylated MGP binds Ca²⁺ and adsorbs to hydroxyapatite, directly inhibiting nucleation/growth of mineral crystals in the extracellular matrix. This is a core anti-calcification mechanism in vessels and soft tissues. | Hydroxyapatite binding and inhibition of crystal growth (pqac-00000000, pqac-00000001, pqac-00000004, pqac-00000008, pqac-00000009) | Galunska et al., 2024; https://doi.org/10.3390/ijms25063517. Neofytou et al., 2024; https://doi.org/10.3390/nu16121798. |
| Major mechanism: fetuin-A / mineral complexes | Active MGP can participate in mineralization complexes with fetuin-A, calcium, and phosphate, limiting crystal growth and promoting clearance of mineral-containing complexes/apoptotic material. | Fetuin-A/Ca–PO4 complex formation and phagocytic clearance model (pqac-00000000, pqac-00000005, pqac-00000008, pqac-00000022) | Galunska et al., 2024; https://doi.org/10.3390/ijms25063517. |
| Major mechanism: BMP-2/4 antagonism | MGP binds BMP-2 and BMP-4 in a Ca²⁺/Gla-dependent manner and blocks BMP-driven osteogenic/chondrogenic conversion of vascular smooth muscle cells, thereby suppressing a key signaling route to vascular calcification. | BMP-2/4 antagonism and dependence on Gla/Ca²⁺ (pqac-00000000, pqac-00000002, pqac-00000008, pqac-00000009, pqac-00000013) | Galunska et al., 2024; https://doi.org/10.3390/ijms25063517. Lau, 2025 thesis/source (no DOI in evidence). |
| Localization / expressing cell types | MGP is secreted into extracellular matrix, especially in arterial wall/cartilage environments. It is produced by vascular smooth muscle cells, chondrocytes, fibroblasts, endothelial cells, and also reported in osteoblast/osteoclast-related contexts; tissue expression includes arteries, heart, kidney, lung, bone, and cartilage. | Cell types and tissue distribution (pqac-00000000, pqac-00000002, pqac-00000007, pqac-00000010) | Galunska et al., 2024; https://doi.org/10.3390/ijms25063517. Neofytou et al., 2024; https://doi.org/10.3390/nu16121798. |
| Disease relevance / genetics | MGP is one of the strongest endogenous inhibitors of vascular and soft-tissue calcification. Human deficiency causes Keutel syndrome, while Mgp knockout animals develop rapid arterial/cartilage calcification and aortic rupture, supporting a causal anti-mineralization role rather than a passive association. | Human/animal loss-of-function phenotypes (pqac-00000007, pqac-00000009, pqac-00000010, pqac-00000012) | Neofytou et al., 2024; https://doi.org/10.3390/nu16121798. Zhang et al., 2023; https://doi.org/10.3892/ijmm.2023.5330. |
| Translational note: dp-ucMGP biomarker | Circulating dp-ucMGP (dephospho-uncarboxylated MGP) is the fully inactive form and an inverse biomarker of extrahepatic vitamin K status. It is widely studied in CKD/CVD risk stratification, but its specificity as a calcification marker remains imperfect and context-dependent. | Biomarker interpretation and cautions (pqac-00000000, pqac-00000011, pqac-00000019, pqac-00000020) | Galunska et al., 2024; https://doi.org/10.3390/ijms25063517. Nyvad et al., 2024; https://doi.org/10.1186/s12882-024-03876-5. |
| Recent quantitative biomarker / intervention data | In 4,092 adults, each doubling of dp-ucMGP associated with central obesity OR 4.76, diabetes OR 1.96, hyperlipidaemia OR 1.43, and impaired kidney function OR 9.83; no independent association with hypertension or arterial stiffness. In a 2023 meta-analysis of 11 randomized dialysis trials (830 participants), vitamin K lowered dp-ucMGP, with larger pooled effects for K1 (SMD −1.64) than K2 (SMD −0.56), but without clear mortality or calcification-score benefit. | Population-level ORs; trial/meta-analysis effect sizes (pqac-00000016, pqac-00000021) | Lauridsen et al., 2025 online/2024 DOI record; https://doi.org/10.1007/s00394-024-03532-6. Andrian et al., 2023; https://doi.org/10.1093/ckj/sfad255. |


*Table: This table summarizes verified functional annotation facts for human Matrix Gla protein (MGP; UniProt P08493), including core biochemistry, mechanisms, localization, and translational biomarker relevance. It is designed as a compact evidence map for use in a gene-focused research report.*